# Impact of Intrathecal Morphine on Sleep Apnea Syndrome

> **NCT02566226** · PHASE4 · COMPLETED · sponsor: **Centre Hospitalier Universitaire Vaudois** · enrollment: 60 (actual)

## Conditions studied

- Sleep Apnea Syndromes

## Interventions

- **DRUG:** Bupivacaine with normal saline
- **DRUG:** Bupivacaine with intrathecal morphine

## Key facts

- **NCT ID:** NCT02566226
- **Lead sponsor:** Centre Hospitalier Universitaire Vaudois
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2019-03
- **Final completion:** 2019-03
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2019-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02566226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02566226, "Impact of Intrathecal Morphine on Sleep Apnea Syndrome". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02566226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*